Prepare to dive into the TWILIGHT trial with Dr. Craig Beavers.
0:00-0:22: Intro
0:23-1:01: Introduction of Dr. Craig Beavers
1:02-3:32: TWILIGHT Overview
3:33-6:31: Craig’s Overall Thoughts
6:32-8:39: Excluded Patients
8:40-10:17: Ticagrelor Monotherapy and Ischemic Outcomes
10:18-12:52: TWILIGHT and GLOBAL LEADERS
12:53-14:24: Final Thoughts
14:25-15:22: Closing/Craig’s Upcoming Podcast
References:
- TWILIGHT: Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med 2019;381:2032-2042.
- GLOBAL LEADERS: Vranckx P, Valgimigli M, Juni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018;392:940-49.
Episode is Live
Published: Dec. 24, 2019 @ 4AM EditUnpublish
CardioScripts 